Xoma - Biotechperle!! - Gutes Langfristinvestement

Gruß Pichel

Umsatz 489.985
High 2,80
Low 2,22  

Gruß Pichel

Da muss man direkt an der Nasdaq ran.

Ich habe schon seit Wochen keine mehr
in BRD nachkaufen können.

Die letzten Zahlen wurden übrigens überwiegend
positiv beurteilt.
Ich selber sehe jedoch nur, dass denen bald das Geld
ausgeht.
Also fundamental bin ich heute weniger überzeugt
als früher.
Aber da aktuell QualitÄt á la Rösch, Achterbahn etc.
steigt (und wohl ähnlicher Schrott ihn USA) ist deCode
längst überfällig.

Aber wenn die uns mal die Achterbahn machen,
bin ich mit dabei (auch wenn's gerne mehr
Stücke sein dürften).

Intraday, sind abverkauft worden, aber heftige Entwicklung.

Gruss E.

aber es wird mächtig decodiert zur Zeit.

Gruß Pichel

Was Lalapo seine TA sind mir DCGN.
Da kein Dollar-Handel für mich habe ich um
die wenigen Stücke so kämpfen müssen (in den letzten Wochen
keine neuen zu realen Preisen bekommen können),
dass das laaaaangfristig bei mir ist.

Wenn Du in USA handelst, solltest Du bei Drehen der allg. Marktstimmung
durchaus Gewinne sichern.
Ich weiß immer noch keinen Grund für den Anstieg, ausser
Biotope generell in USA.

Gruß
       baanbruch

is wohl etwas zu viel des Guten....
bin froh wenn ich die Stücke, die ich hier in Deutschland gekauft habe, wieder los werde! Hätte damals auch in USA kaufen sollen!

Gruß Pichel

Position seit 28.1. zu 3,- und NK 2,- endlich !

Gruß Pichel

Was hast Du da bloß losgetreten !

Monatelang fast gar nix, und jetzt tanzt der Bär
(oder vielleicht doch der Bulle ?)

Na ja, wenn Du nicht davon überzeugt warst.
Ich bin's!
Für so ein Almosen gebe ich kein Stück ab.

Gruß Pichel

der aktuellen Biotope-Hysterie der Amis mit.

Möchte den geneigten Lesern trotzdem 2 nicht ganz unwichtige
News zu DCGN mitteilen.

In Island wurde vor kurzem gewählt und die neue Regierung
ist mehr oder weniger die alte.
Der alte/neue Premierminister ist als Gönner (Staatsgarantien und so)
von DeCode bekannt.

Trotz Entlassung von schon sehr vielen Mitarbeitern
wurde heute die Entlassung von weiteren 28 bekannt gegeben.
Diese kommen fast alle aus dem Computerbereich und nicht aus dem Labor.
Hiermit soll das weitere Aufzehren der liquiden Mittel bekämpft werden.

So, wenn sie sich vom aktuellen Kurs verdreifachen und der Dollar sich
erholt, dann wären sie zweistellig.
Kann nur noch 1 oder 2 Jahre dauern!

Wohl weil ich auch keine Avaya, keine Baader
keine Infor und keine DAB-Bank gekauft habe.

Blöde muss der Mensch sein.
Oder grottenschlechtes Timing haben!

(Wären jetzt 300% gewesen!)

30% an einem Tag habe ich auch lange nicht
mehr gehabt.
Hoffentlich fällt nicht Montag wieder alles in sich zusammen.

(issich wegen news bezgl. Test mit Roche).

dass ich die news schon vor Börseneröffnung
hätte lesen können, wenn ich nur nach USA gekuckt hätte.

Ob ich allerdings in BRD zu 4,40 heute morgen noch bedient
worden wäre, steht auf einem ganz anderen Blatt.

Na, Pichel, nu is zweistellig doch gar nicht mehr sooooooo
illusionär, oder ?

Gruß
baanbruch

Nach dem starken Anstieg am Freitag sind ja
eigentlich Gewinnmitnahmen zu erwarten.
Andererseits gab es gestern im hohen Norden
höchst interessante news, dass man nämlich
jetzt eine Datenbank über Krebsfälle der letzten
50 Jahre fertig habe.
Wenn der Umsatz in BRD nicht so gering wäre, würde
ich fast zum Nachfassen raten.

Mal sehen, ob ich richtig liege. Die 7 Dollar
könnten heute in USA fallen.

Amevive, which is given intravenously or by injection, suppresses immune system T-cells that play a central role in psoriasis. It is long-acting, but patients must be monitored due to concerns it might compromise their immune systems.

A spokeswoman for Genentech said the FDA did not require physician-monitoring of Raptiva, other than advising doctors to look out for a drop in blood platelets, which are necessary for blood to clot.

"Raptiva fills a gap in the marketplace ... it offers continuous control of psoriasis in a once-weekly injection," said Diane Parks, Genentech's manager of specialty biotherapeutics.

She expects Enbrel to be Raptiva's chief competition. "At the end of the day, there is room for two biologics in the market," Parks said.

Kevin Young, general manager of Amgen's inflammation unit, said he expects FDA approval of Enbrel in psoriasis next year. "Our balance between safety and efficacy is what dermatologists want," he said. "Starting patients on Raptiva, and especially stopping them, has its challenges."

Some side effects of Raptiva included headaches, chills, fever and nausea, and the drug increase the risk of infection. In addition, the psoriasis flared up when patients stopped taking the drug.

The exact cause of psoriasis is not known, but experts believe it is related to an overactive immune system that may contribute to the abnormal growth of skin cells.

A normal skin cell usually matures in a month and is shed from the skin's surface unnoticed, but a psoriatic skin cell takes only a few days to mature and move to the surface, and the cells pile up and form raised, red lesions.

Raptiva, estimated by analysts to eventually reach peak sales of about $400 million a year, is not expected to be a blockbuster drug for Genentech, but it would be Xoma's first commercial product.

The companies submitted the latest application to the FDA in December. They first sought approval last April, but the agency asked for confirmation that Genentech facilities could duplicate earlier batches of the drug without changing its chemical composition.




Email this story - Set a News Alert

Net loss for the third quarter 2003 was $1.3 million. Net loss for the third quarter of 2002 was $85.4 million, including $64.8 million of impairment, employee termination costs and other charges. Excluding these items, net loss for the third quarter 2002 was $20.6 million. Compared to this figure, net loss for the third quarter 2003 decreased by 94% versus the year ago period. For the first nine months of 2003 net loss decreased by 56% to $24.6 million compared to the $56.2 million for the first nine months of 2002, which is also exclusive of the charges in the latter period. Higher revenues and the introduction of significant operational efficiencies in the latter half of last year were the principal factors in these reductions.

Basic and diluted net loss per share decreased to $0.03 for the third quarter 2003 from $1.68 for the same quarter last year. Basic and diluted net loss per share for the first nine months of 2003 was $0.48, versus $2.50 for the first nine months of 2002. At the close of the third quarter the company had approximately 53.8 million shares outstanding.

Research and development expenses during the third quarter were $11.1 million, including a one-time, non-cash reversal of accrued license fees amounting to $3.2 million. Excluding this reversal, R&D expenses for the third quarter were $14.3 million, 40% lower than the $23.9 million in the third quarter 2002. For the first nine months of 2003, R&D expenses were $47.5 million. Excluding the one-time reversal in the third quarter, R&D expenses for the first nine months of this year were $50.7 million compared to $66.6 million for the 2002 period, a 24% decrease. These reductions are the result principally of the company's efforts over the past year to take advantage of investments in automation in its gene research programs and to focus resources on product development.

Selling, general and administrative expenses for the third quarter decreased by 31% versus last year, to $4.0 million for the period in 2003 from $5.8 million for the period in 2002. SG&A expenses for the first nine months of 2003 were $12.0 million, compared to $14.2 million for the first nine months of 2002, representing a decrease of 16%. These decreases are principally due to the streamlining of the company's operations undertaken last year.

At the close of the third quarter, the company had $78.4 million in cash and cash equivalents, including $6 million in restricted cash. This is $1.8 million more than at the close of the second quarter, an increase resulting mainly from the significantly lower net loss for the quarter and the collection of receivables.

"Our strong results for the quarter are the fruit of our efforts to accelerate our target discovery work and to channel our resources directly into product development. By maintaining our focus on increasing revenue while driving down costs, we have achieved positive cashflow from our current operations for the quarter and have in hand the resources necessary to bring our lead therapeutic and diagnostic products into the clinic," said Dr. Kari Stefansson, President and Chief Executive Officer of deCODE. "In recent weeks we have announced several examples of how our genetics work is yielding exciting new targets for both drug and diagnostic development. The coming months promise to be an important period in deCODE's growth and I look forward to sharing with you our progress in advancing our product pipeline. Our successes this year have positioned us well to take a leading role in applying the new genetics to improve the diagnosis, treatment and prevention of many of the most common diseases in our society."

   Recent company highlights include:

   Research and Development

    * Obesity.  deCODE announced the achievement of a milestone under its
      alliance with Merck to develop novel treatments for obesity.  Through
      genotypic analysis involving more than 1000 women participants in its
      obesity program, deCODE scientists isolated a gene which in one form
      predisposes to obesity and in another form predisposes to thinness.
      The companies are using this information in their drug discovery
      program.

    * Myocardial infarction.  deCODE and Roche Diagnostics announced a
      landmark discovery under their alliance to develop DNA-based diagnostic
      tests for common diseases.  deCODE scientists identified forms of a
      gene that confer approximately twice the average risk of myocardial
      infarction, or heart attack.  The companies plan to use this
      information in the development of a DNA-based test to identify
      individuals who are at elevated risk, thereby facilitating the
      implementation of preventive measures that can help to minimize the
      risk of these individuals ever suffering a heart attack.  The two
      at-risk haplotypes, or forms of the gene, each delineated by only 6
      SNPs, are both common and were found to confer significant risk of
      heart attack in the Icelandic population.  These haplotypes confer
      risks equal to or greater than those conferred by other well-known risk
      factors such as smoking, high blood pressure, high cholesterol or
      diabetes.

    * Stroke.  deCODE's study identifying the first gene ever linked to
      common forms of stroke was published in the October edition of Nature
      Genetics, in a paper entitled "The Phosphodiesterase 4D gene confers
      risk to ischemic stroke."  The deCODE team identified the PDE4D gene
      and significant haplotypes by analyzing detailed genotypic data from
      1800 participants in the company's stroke program, both patients and
      unaffected relatives, from across Iceland.  The study demonstrates that
      variations in the PDE4D gene are significantly associated with ischemic
      stroke.  Within this gene, the deCODE team identified haplotypes, or
      specific sets of genetic markers, that correspond both to significantly
      increased risk of stroke and to significantly decreased risk.  deCODE
      and its drug development partner in this program, Roche, have initiated
      medicinal chemistry work on compounds they have identified as active
      against targets in the PDE4D pathway.  deCODE is also developing a
      DNA-based diagnostic test based upon the at-risk and protective
      haplotypes within the PDE4D gene.

   Finance

    * Cash position.  At the close of the quarter ended September 30, 2003,
      the company had $78.4 million in cash and cash equivalents, including
      $6 million in restricted cash.  This is $1.8 million more than at the
      close of the second quarter, an increase resulting mainly from the
      significantly lower net loss for the quarter and the collection of
      receivables.


About deCODE

deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services -- in gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE's pharmaceuticals group, based in Chicago, and deCODE's biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE's proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at www.decode.com.

Conference Call Information

A conference call, during which deCODE President and CEO Kari Stefansson and Executive Vice President and Senior Business Officer Hannes Smarason will discuss financial results and operating highlights from the quarter, will be webcast tomorrow, Thursday, October 30, at 8am EST/1pm GMT. The webcast can be accessed via the Investors section of deCODE's website, www.decode.com, through www.streetevents.com, or, for non-subscribers to StreetEvents, on www.companyboardroom.com. A replay of the call will be available on these websites for the following week. A digitized telephone replay of the call can be accessed for the week following the call by dialing 1 800 475 6701 from the US, or +1 320 365 3844 from outside the US. The access code is 703702.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results, and the timing of events, to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

        Condensed Consolidated Statements of Operations (unaudited)

                               For the three months      For the nine months
                                ended September 30,      ended September 30,
                                 2003         2002          2003       2002
                           (in thousands, except share and per share amounts)
   Revenue                    $  12,763  $     8,982  $    35,141  $  23,682
   OPERATING EXPENSES
       Research and
        development, including
         cost of revenue         11,068       23,856       47,516     66,634
       Selling, general and
        administrative            3,989        5,753       11,975     14,235
       Impairment, employee
        termination costs and
         other charges              115       64,790          906     64,790
             Total operating
              expense            15,172       94,399       60,397    145,659
   Operating loss                (2,409)     (85,417)     (25,256)  (121,977)
   Interest income                  243          711          897      2,269
   Interest expense                (826)        (589)      (2,603)    (2,199)
   Other non-operating income
    and (expense),  net           1,706         (144)       2,402        560
   Net loss before cumulative
    effect of change in
     accounting principle        (1,286)     (85,439)     (24,560)  (121,347)
   Cumulative effect of change
    in milestone recognition
     method                           0            0            0        333
   Net loss                   $  (1,286) $   (85,439)$    (24,560)$ (121,014)

   Basic and diluted net loss
    per share:
       Net loss before
        cumulative effect of
         change in accounting
          principle           $   (0.03) $     (1.68)$      (0.48)$    (2.51)
       Cumulative effect of
        change in milestone
         revenue recognition
          method              $      --  $        -- $         -- $     0.01
       Net loss               $   (0.03) $     (1.68)$      (0.48)$    (2.50)
   Shares used in computing
    basic and diluted net
     loss per share          51,399,816   50,958,332   51,262,995 48,425,673


    Contact:
    deCODE genetics
    Joy Bessenger            Edward Farmer
    +354 570-1951            +354 570 1900
    +1 (212) 481-3891        info@decode.is
    ir@decode.is




--------------------------------------------------
Source: deCODE genetics

Email this story - Set a News Alert

7:38AM XOMA Limited misses by $0.02, beats on revs (XOMA) 6.84: Reports Q3 (Sep) loss of $0.13 per share, $0.02 worse than the Reuters Research consensus of ($0.11); revenues rose 198.6% year/year to $12.6 mln vs the $10.4 mln consensus.

Na ja, 20 cents fehlen noch!
News hierfür habe ich keine.
Die Ankündigung der Konferenz reicht ja wohl nicht.

deCODE genetics to Webcast R&D Day
Thursday November 13, 8:12 am ET


REYKJAVIK, Iceland, Nov. 13 /PRNewswire-FirstCall/ -. deCODE genetics (Nasdaq: DCGN - News) today announced that it will webcast live the presentations at its first annual U.S. R&D Day to be held next week in New York City. deCODE management will provide an in-depth discussion of the company's population genetics work and drug and diagnostics development programs.
The event will take place on Wednesday, November 19, 2003, and speakers will include Kari Stefansson, President and Chief Executive Officer; Jeffrey Gulcher, Vice President of Research and Development; Mark Gurney, Vice President of Drug Discovery; and Hakon Hakonarson, Vice President of Clinical Development. The presentations are scheduled to begin at 9am EST/2pm GMT and conclude at 12:30pm EST/5:30pm GMT. The webcast can be accessed through the Investors page on deCODE's website, www.decode.com, or through www.fulldisclosure.com. Those interested in listening to the presentation should log on a few minutes in advance, in order to download any software or complete any sign-in that may be required.

deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services -- in gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE's pharmaceuticals group, based in Chicago, and deCODE's biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE's proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at www.decode.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

    Contact:
    deCODE genetics
    Kristin Asgeirsdottir      Joy Bessenger
    +354 570 1950              +1 212 481 3891
    ir@decode.is               ir@decode.is




--------------------------------------------------
Source: deCODE genetics